SVFCX
Price
$76.95
Change
-$1.53 (-1.95%)
Updated
Feb 21 closing price
Net Assets
5.83B
VIVIX
Price
$68.78
Change
-$0.82 (-1.18%)
Updated
Feb 21 closing price
Net Assets
192.55B
Ad is loading...

SVFCX vs VIVIX

Header iconSVFCX vs VIVIX Comparison
Open Charts SVFCX vs VIVIXBanner chart's image
Smead Value C
Price$76.95
Change-$1.53 (-1.95%)
VolumeN/A
Net Assets5.83B
Vanguard Value Index I
Price$68.78
Change-$0.82 (-1.18%)
VolumeN/A
Net Assets192.55B
SVFCX vs VIVIX Comparison Chart
Loading...
View a ticker or compare two or three
VS
SVFCX vs. VIVIX commentary
Feb 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SVFCX is a Hold and VIVIX is a StrongBuy.

Ad is loading...
FUNDAMENTALS
Fundamentals
VIVIX has more cash in the bank: 193B vs. SVFCX (5.83B). VIVIX pays higher dividends than SVFCX: VIVIX (2.37) vs SVFCX (0.80). SVFCX was incepted earlier than VIVIX: SVFCX (5 years) vs VIVIX (27 years). SVFCX is a more actively managed with annual turnover of: 15.60 vs. VIVIX (10.00). SVFCX has a lower initial minimum investment than VIVIX: SVFCX (25000) vs VIVIX (5000000). VIVIX annual gain was more profitable for investors over the last year : 16.23 vs. SVFCX (4.64).
SVFCXVIVIXSVFCX / VIVIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence5 years27 years-
Gain YTD2.8015.84648%
Front LoadN/AN/A-
Min. Initial Investment2500050000001%
Min. Initial Investment IRAN/AN/A-
Net Assets5.83B193B3%
Annual Yield % from dividends0.802.3734%
Returns for 1 year4.6416.2329%
Returns for 3 years21.0525.0484%
Returns for 5 yearsN/A49.57-
Returns for 10 yearsN/A109.78-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FSM4.830.22
+4.77%
Fortuna Mining Corp
GOLF66.370.46
+0.70%
Acushnet Holdings Corp
XEL69.320.25
+0.36%
Xcel Energy
EMKR3.100.01
+0.16%
EMCORE Corp
LXRX0.73-0.02
-2.05%
Lexicon Pharmaceuticals